Status:
COMPLETED
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
Lead Sponsor:
Tufts Medical Center
Conditions:
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to learn if dietary habits can affect vasopressin secretion in patients with autosomal dominant polycystic kidney disease. Vasopressin increases the growth of kidney cysts...
Detailed Description
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease with an estimated 600,000 persons affected in the United States and 12.5 million persons worldwide. To...
Eligibility Criteria
Inclusion
- Adults 18 to 60 years of age, who have ADPKD with an estimated glomerular filtration rate (eGFR) of 60 ml/min/1.73m2 or above
Exclusion
- Patients on chronic use of medications known to affect AVP secretion (Serotonin Specific Reuptake inhibitors (SSRI), Opioids, Tricyclic Antidepressants (TCA) and Tolvaptan)
- History of diseases influencing renal concentration capacity, such as, diabetes insipidus, adrenal or thyroid deficiencies, present or prior use of lithium, or kidney diseases other than ADPKD.
- Baseline hyponatremia (Na below 135 mEq/l)
- Inability to comply with dietary or fluid requirements
- Have physical or cognitive impairments which prevent participation
- Pregnant women
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT02225860
Start Date
May 1 2014
End Date
February 1 2016
Last Update
March 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tufts Medical Center
Boston, Massachusetts, United States, 02111